Optimal follow-up intervals for different stages of chronic kidney disease: a prospective observational study

被引:8
|
作者
Hirano, Keita [1 ,2 ]
Kobayashi, Daiki [3 ]
Kohtani, Naoto [4 ]
Uemura, Yukari [5 ]
Ohashi, Yasuo [6 ]
Komatsu, Yasuhiro [2 ,7 ]
Yanagita, Motoko [1 ]
Hishida, Akira [8 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Nephrol, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto 6068507, Japan
[2] St Lukes Int Hosp, Dept Nephrol, Tokyo, Japan
[3] St Lukes Int Hosp, Div Gen Internal Med, Dept Med, Tokyo, Japan
[4] Pharmaceut & Med Devices Agcy, Ctr Prod Evaluat, Biostat Grp, Tokyo, Japan
[5] Univ Tokyo Hosp, Biostat Div, Cent Coordinating Unit, Clin Res Support Ctr, Tokyo, Japan
[6] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, Tokyo, Japan
[7] Gunma Univ, Dept Healthcare Qual & Safety, Grad Sch Med, Gunma, Japan
[8] Yaizu City Hosp, Yaizu, Shizuoka, Japan
关键词
Testing interval; Chronic kidney disease; CKD-JAC; Cohort study; AKAIKE INFORMATION CRITERION; CARDIOVASCULAR EVENTS; COST-EFFECTIVENESS; MODEL SELECTION; CLINICAL-TRIALS; END-POINTS; CKD; CANCER; RISK; FOUNDATION;
D O I
10.1007/s10157-018-01684-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Chronic kidney disease (CKD) is a public health challenge; however, evidence-based, optimal follow-up intervals for patients with CKD have not been identified. This study aimed to identify appropriate follow-up intervals for different stages of CKD. Methods We studied 2682 patients with CKD. The number of patients experiencing a 50% increase in creatinine and those reaching end-stage renal failure were examined on the basis of their CKD stage. The renal function testing interval was defined as the estimated time for 0.1% of the patients with CKD to have a composite renal outcome, after adjusting for clinical risk factors. Transitions from CKD stage-based subgroups were analyzed using parametric cumulative incidence models. Other sensitivity analyses involved estimation of the time to renal event occurrence for 1% of patients. Results Of the 913 patients (34%) who had a composite renal event, 29 had stage 3A (10.5%), 151 had stage 3B (16.3%), 429 had stage 4 (41.0%), and 304 had stage 5 CKD (70.9%). The estimated renal function testing intervals for patients with CKD were 6.0 months for stage 3A, 3.4 months for stage 3B, 2.0 months for stage 4, and 1.2 months for stage 5. Conclusions The optimal follow-up intervals were longer for patients with lower CKD stages. These estimates are longer than those recommended by the current guidelines and serve as a reference for nephrologists in selecting an appropriate follow-up interval for each patient.
引用
收藏
页码:613 / 620
页数:8
相关论文
共 50 条
  • [1] Optimal follow-up intervals for different stages of chronic kidney disease: a prospective observational study
    Keita Hirano
    Daiki Kobayashi
    Naoto Kohtani
    Yukari Uemura
    Yasuo Ohashi
    Yasuhiro Komatsu
    Motoko Yanagita
    Akira Hishida
    Clinical and Experimental Nephrology, 2019, 23 : 613 - 620
  • [2] Pulmonary Manifestations at Different Stages in the Chronic Kidney Disease: An Observational Study
    Mani, Anbumaran Parivakkam
    Shanmugapriya, K.
    Sundar, Raja
    Yadav, Sankalp
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [3] Endothelial Progenitor Cells and Cardiovascular Events in Patients with Chronic Kidney Disease - a Prospective Follow-Up Study
    Lorenzen, Johan
    David, Sascha
    Bahlmann, Ferdinand H.
    de Groot, Kirsten
    Bahlmann, Elisabeth
    Kielstein, Jan T.
    Haller, Hermann
    Fliser, Danilo
    PLOS ONE, 2010, 5 (07):
  • [4] PROSPECTIVE STUDY ON OCCURRENCE AND MANAGEMENT OF CHRONIC SINOATRIAL DISEASE, WITH FOLLOW-UP
    ROKSETH, R
    HATLE, L
    BRITISH HEART JOURNAL, 1974, 36 (06): : 582 - 587
  • [5] RAPIDIRON Trial follow-up study - the RAPIDIRON-KIDS Study: protocol of a prospective observational follow-up study
    Derman, Richard J.
    Bellad, Roopa B.
    Bellad, Mrutyunjaya B.
    Bradford-Rogers, Jesse
    Georgieff, Michael K.
    Aghai, Zubair H.
    Thind, Simal
    Auerbach, Michael
    Boelig, Rupsa
    Leiby, Benjamin E.
    Short, Vanessa
    Yogeshkumar, S.
    Charantimath, Umesh S.
    Somannavar, Manjunath S.
    Mallapur, Ashalata A.
    Pol, Ramesh
    Ramadurg, Umesh
    Sangavi, Radha
    Peerapur, Basavaraj V.
    Banu, Nasima
    Patil, Praveen S.
    Patil, Amaresh P.
    Roy, Subarna
    Vastrad, Phaniraj
    Wallace, Dennis
    Shah, Hemang
    Goudar, Shivaprasad S.
    TRIALS, 2023, 24 (01)
  • [6] RAPIDIRON Trial follow-up study — the RAPIDIRON-KIDS Study: protocol of a prospective observational follow-up study
    Richard J. Derman
    Roopa B. Bellad
    Mrutyunjaya B. Bellad
    Jesse Bradford-Rogers
    Michael K. Georgieff
    Zubair H. Aghai
    Simal Thind
    Michael Auerbach
    Rupsa Boelig
    Benjamin E. Leiby
    Vanessa Short
    S. Yogeshkumar
    Umesh S. Charantimath
    Manjunath S. Somannavar
    Ashalata A. Mallapur
    Ramesh Pol
    Umesh Ramadurg
    Radha Sangavi
    Basavaraj V. Peerapur
    Nasima Banu
    Praveen S. Patil
    Amaresh P. Patil
    Subarna Roy
    Phaniraj Vastrad
    Dennis Wallace
    Hemang Shah
    Shivaprasad S. Goudar
    Trials, 24
  • [7] Does Chronic Kidney Disease Have an Impact on the Use of Oral Anticoagulants after Stroke? An Observational Follow-Up Study
    Laible, Mona
    Horstmann, Solveig
    Ringleb, Peter Arthur
    Veltkamp, Roland
    Jenetzky, Ekkehart
    Rizos, Timolaos
    EUROPEAN NEUROLOGY, 2021, 84 (05) : 354 - 360
  • [8] Homeopathic treatment of patients with chronic sinusitis: A prospective observational study with 8 years follow-up
    Witt, Claudia M.
    Luedtke, Rainer
    Willich, Stefan N.
    BMC EAR NOSE AND THROAT DISORDERS, 2009, 9
  • [9] What are the Optimal Intervals for Food Allergy Follow-Up?
    Schuval, Susan
    Sabbatini, Carla
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB250 - AB250
  • [10] Impact of educational level on incident chronic kidney disease during 13 years of follow-up: a prospective cohort study
    Barzegar, N.
    Tohidi, M.
    Ghodssi-Ghassemabadi, R.
    Amiri, P.
    Azizi, F.
    Hadaegh, F.
    PUBLIC HEALTH, 2021, 195 : 98 - 104